What Is Retatrutide and How Does It Work in 2026?

Retatrutide (CAS Registry Number: 2381089-83-2) is a synthetic 39-amino acid peptide engineered as a triple receptor agonist. It is structurally based on a native GIP peptide backbone, with targeted amino acid modifications and a C20 fatty diacid side chain to extend its half-life to approximately 6 days, supporting once-weekly dosing.

It was developed and is currently in late-stage Phase 3 clinical trials. As of mid-2026, it has not received regulatory approval for clinical use in any global region, and is primarily used in pharmaceutical R&D and API supply chains.

Key facts at a glance:

• Drug class: Triple receptor agonist peptide
• Primary indications: Obesity, type 2 diabetes, MASH
• CAS number: 2381089-83-2
• Half-life: ~6 days
• Development stage: Phase 3
• Administration: Once-weekly subcutaneous injection

Retatrutide works by simultaneously activating three key metabolic hormone receptors: GIP, GLP-1, and glucagon. Together, these three pathways regulate both sides of the body's energy balance equation, achieving dual regulation of energy intake and consumption that single/dual agonists cannot match:

• Reduced appetite and caloric intake (via GLP-1 and GIP action on the hypothalamus): Suppresses excessive food cravings and long-term calorie overconsumption, laying the foundation for sustained weight loss
• Improved insulin sensitivity and fat breakdown (via GIP action on adipose tissue): Reduces insulin resistance, accelerates subcutaneous and visceral fat decomposition, and improves metabolic disorders
• Increased resting energy expenditure and hepatic fat oxidation (via glucagon action on the liver): Elevates basal metabolism, consumes accumulated liver fat, and avoids weight loss plateau common with single-target drugs

2026 Clinical Data Summary

As of July 2026, two pivotal Phase 3 trials have released topline results confirming retatrutide's superior efficacy and reliable safety profile, setting a new efficacy benchmark for metabolic peptide drugs:

TRIUMPH-1 

1. 2,339 adults with obesity/overweight and weight-related comorbidities (no diabetes)
2. 12mg dose achieved 28.3% average weight loss at 80 weeks
3. 65.3% of patients reached a BMI below 30 kg/m²
4. Extended follow-up showed 30.3% average weight loss at 104 weeks in high-BMI subgroups, with no observed weight plateau

TRANSCEND-T2D-1 

• Adults with inadequately controlled type 2 diabetes
• 12mg dose achieved 2.0% HbA1c reduction and 16.8% average weight loss at 40 weeks

Headline efficacy and development status comparison between retatrutide and mainstream approved metabolic peptides:

Retatrutide API Supply & Quality Overview

High-purity retatrutide API is manufactured via solid-phase peptide synthesis (SPPS), followed by multi-step HPLC purification and full quality control testing. GMP-grade API is mandatory for all preclinical and clinical development activities, with strict industry-standard quality thresholds for pharmaceutical-grade applications.

Key quality standards for pharmaceutical-grade retatrutide API:

• Minimum 98% HPLC purity (99% mandatory for preclinical/clinical use)
• Full batch-specific COA with LC-MS, endotoxin, heavy metal, and residual solvent testing
• Manufactured in ISO-certified GMP-compliant cleanroom facilities
• Stable batch-to-batch consistency and scalable kg/ton-level annual production capacity

Q: What is the mechanism of action of retatrutide in weight loss?

A: Retatrutide acts as a triple GIP/GLP-1/glucagon agonist. GLP-1 and GIP suppress appetite to cut calorie intake, GIP boosts insulin sensitivity and fat decomposition, and glucagon raises resting metabolism plus liver fat oxidation. The three combined pathways create stronger fat loss results than single or dual-target peptide drugs, supporting continuous, plateau-free weight loss.

Q: Is retatrutide FDA approved?

A: As of mid-2026, retatrutide is still in Phase 3 clinical development and has not received FDA or any other global regulatory approval for clinical use. It is currently only available for pharmaceutical R&D and manufacturing purposes.

Q: How much weight can you lose with retatrutide?

A: In Phase 3 clinical trials, the 12mg dose of retatrutide produced an average weight loss of 28.3% over 80 weeks in adults with obesity, outperforming all approved GLP-1 and dual agonist therapies. Individual results may vary based on baseline BMI and physical condition.

Q: What is the difference between retatrutide and tirzepatide?

A: The primary difference is receptor targets: tirzepatide is a dual GIP/GLP-1 agonist, while retatrutide is a triple GIP/GLP-1/glucagon agonist. The additional glucagon receptor activity increases energy expenditure and fat oxidation, resulting in greater weight loss efficacy in clinical trials.

Q: What is the CAS number for retatrutide?

A: The CAS registry number for retatrutide is 2381089-83-2.

Q: Can I buy retatrutide API for research use?

A: Yes, GMP-grade retatrutide raw powder is available from qualified peptide API manufacturers for pharmaceutical R&D and formulation development use. It is not intended for personal human use.

Access exclusive professional resources and customized procurement services to accelerate your R&D and bulk supply layout:

• Download Clinical + Procurement Full Package – Complete Phase 3 trial data report + API quality standard checklist
• Get GMP Retatrutide API COA in 24h – Batch-specific full qualification documents for project review and R&D filing
• Request China Manufacturer Audit Report – Factory qualification, production capacity and GMP compliance verification files
• Apply for Bulk Supply Evaluation & Custom Quotation – Free sample testing, kg/ton-level bulk pricing and exclusive supply solution

Disclaimer

This hub guide is for informational purposes only and is intended exclusively for pharmaceutical industry R&D and procurement professionals. Retatrutide is an investigational compound not approved for commercial clinical use globally. It is prohibited for personal human injection or off-label weight-loss self-administration. All clinical and quality data referenced is sourced from publicly released trial results and global ICH GMP industry standards as of mid-2026.